Grufity logoGrufity logo

ABT

103.78USD-1.63(-1.55%)Delayedas of 06 Dec 2022, 12:40 pm

Abbott Laboratories

Market Summary

USD103.78-1.63Delayedas of 06 Dec 2022, 12:40 pm
-1.55%

ABT Alerts

ABT Stock Price

RSI Chart

Valuation

Market Cap

174.5B

Price/Earnings

20.4

Price/Sales

3.83

Price/Cashflow

17.04

MarketCap/EBT

17.37

Price/Sales

Profitability

EBT Margin

22.06%

Return on Equity

23.44%

Return on Assets

11.53%

Fundamentals

Revenue

Revenue (TTM)

45.0B

Revenue Y/Y

-4.74%

Revenue Q/Q

-7.52%

Earnings

Earnings (TTM)

7.9B

Earnings Y/Y

-31.67%

Earnings Q/Q

-28.89%

Price Action

52 Week Range

93.25140.25
(Low)(High)

Last 7 days

0.0%

Last 30 days

7.5%

Last 90 days

3.1%

Trailing 12 Months

-17.7%

Financial Health

Current Ratio

2.01

Debt/Equity

0.49

Debt/Cashflow

0.57

Investor Care

Dividend Yield

1.35%

Buy Backs (1Y)

1.42%

Diluted EPS (TTM)

4.43

Peers (Alternatives to Abbott Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.3B
31.3B
8.50% -14.15%
27.1
5.87
11.35% 14.95%
174.5B
45.0B
7.48% -17.73%
20.4
3.83
6.43% 8.90%
115.4B
30.8B
-6.92% -24.79%
22.17
3.71
-3.11% -8.14%
86.3B
6.1B
12.60% -16.14%
62.6
14.1
11.47% -18.42%
30.3B
3.3B
13.59% -28.00%
45.68
9.17
6.53% -11.52%
MID-CAP
6.4B
806.4M
30.84% -10.95%
-331.15
7.96
20.10% -221.96%
3.7B
2.3B
3.07% -36.74%
3.27
1.42
24.87% 6.11%
SMALL-CAP
1.4B
527.2M
16.14% -59.87%
29.31
2.69
12.53% -20.65%
1.4B
233.4M
1.11% -71.27%
-4.82
6.12
8.78% -318.40%
765.9M
259.0M
3.86% -58.24%
-43.31
2.97
3.62% -967.02%
470.4M
100.0M
2.59% -18.03%
-105.5
4.8
-4.93% -316.24%
255.1M
71.7M
54.95% 23.28%
-7.11
3.72
20.17% -128.83%
83.1M
-
0.56% -46.89%
-2.75
801.64
4.35% 34.70%
55.9M
56.0M
-12.63% -18.27%
-6.98
1
0.78% -183.24%
2.7M
659.0K
-66.21% -40.16%
-0.05
4.15
-36.14% -68.16%

Financials for Abbott Laboratories

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-1.1%45,03045,54844,51443,07542,308
  S&GA Expenses-0.3%11,32311,35911,32811,32410,846
  R&D Expenses3.9%2,9252,8152,7852,7422,678
Earnings Before Taxes-7.3%9,31310,0489,0448,2118,272
Net Income-7.8%7,8898,5547,7257,0717,244
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.9%72,80174,20274,00775,19673,795
  Current Assets-0.4%24,84524,95623,42924,23923,492
    Cash Equivalents7.4%9,5948,9377,6759,7999,302
  Inventory-2.8%5,7345,8995,6915,1575,261
  Net PPE-1.5%8,6898,8188,9088,9598,831
  Goodwill-2.0%22,28422,74423,17923,20023,300
  Current Liabilities7.9%13,36512,39212,64713,10512,867
.    Short Term Borrowings-100.0%-197---
  Long Term Debt-18,050----
    LT Debt, Current22240.0%1,11754754754
    LT Debt, Non Current-8.7%15,29716,75517,08617,29617,446
Shareholder's Equity-2.2%35,67536,49035,39935,80234,422
  Retained Earnings1.8%35,11534,48733,29531,52830,376
Accumulated Depreciation-0.2%10,61710,64010,61310,40510,351
Shares Outstanding-0.5%1,7541,7621,775--
Minority Interest-7.5%209226230222216
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations0.8%10,32210,2439,96110,53311,264
  Share Based Compensation1.3%676667657640632
Cashflow From Investing8.6%-1,779.00-1,946.00-1,946.00-2,008.00-2,068.00
Cashflow From Financing-2.1%-8,065.00-7,899.00-8,350.00-5,494.00-4,395.00
  Dividend Payments0.8%3,2593,2343,2023,045
  Buy Backs5.7%4,0843,8654,3312,2991,486

Risks

What is the probability of a big loss on ABT?

30.4%


Probability that Abbott Laboratories stock will be more than 20% underwater in next one year

4.2%


Probability that Abbott Laboratories stock will be more than 30% underwater in next one year.

0%


Probability that Abbott Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abbott Laboratories was unfortunately bought at previous high price.

Returns

Cumulative Returns on ABT

15.3%


10-Year Cumulative Returns

14.8%


7-Year Cumulative Returns

15.9%


5-Year Cumulative Returns

9.0%


3-Year Cumulative Returns

What are the long-term rolling returns for ABT?

FIve years rolling returns for Abbott Laboratories.

Which funds bought or sold ABT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
SALEM CAPITAL MANAGEMENT INC
UNCHANGED
-
-192,000
1,557,000
1.23%
2022-11-23
Invst, LLC
REDUCED
-3.76
-28,000
212,000
0.04%
2022-11-23
FSB PREMIER WEALTH MANAGEMENT, INC.
SOLD OFF
-100
-203,000
-
-%
2022-11-23
Toroso Investments, LLC
ADDED
9.23
-137,000
4,890,000
0.20%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-0.49
-121,050
941,000
0.58%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
22,141,000
22,141,000
0.26%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
43.09
1,258,000
5,839,000
0.18%
2022-11-22
SMITH CHAS P & ASSOCIATES PA CPAS
ADDED
0.09
-115,000
939,000
0.08%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
2,643,000
2,643,000
0.10%
2022-11-22
Dash Acquisitions Inc.
ADDED
6.39
-456,000
8,230,000
4.60%

1–10 of 48

Latest Funds Activity

Are funds buying ABT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ABT

Abbott Laboratories News

The Motley Fool

Got $500? Where to Invest It Before 2023.6 hours ago

ABT Fair Value

Recent SEC filings of Abbott Laboratories

View All Filings
Date Filed Form Type Document
Nov 01, 2022
10-Q
Quarterly Report
Oct 31, 2022
4
Insider Trading
Oct 21, 2022
8-K
Current Report
Oct 19, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Sep 21, 2022
3
Insider Trading

Latest Insider Trading transactions for ABT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-27
STARKS DANIEL J
SOLD
-4,872,930
97.4586
-50,000
-
2022-09-08
MANNING JOSEPH J
SOLD
-2,461,860
107
-23,008
EXECUTIVE VICE PRESIDENT
2022-09-08
MANNING JOSEPH J
ACQUIRED
1,021,560
44.4
23,008
EXECUTIVE VICE PRESIDENT
2022-08-25
MANNING JOSEPH J
SOLD
-2,825,090
105.03
-26,898
EXECUTIVE VICE PRESIDENT
2022-08-25
Ford Robert B
ACQUIRED
4,121,870
40.2428
102,425
CHAIRMAN AND CEO
2022-08-25
MANNING JOSEPH J
ACQUIRED
1,021,560
44.4
23,008
EXECUTIVE VICE PRESIDENT
2022-08-25
Ford Robert B
SOLD
-10,765,200
105.103
-102,425
CHAIRMAN AND CEO
2022-08-01
Moreland Mary K
SOLD (Taxes)
-135,506
108.84
-1,245
EXECUTIVE VICE PRESIDENT
2022-07-26
Mateus Fernando
SOLD
-267,943
109.053
-2,457
SENIOR VICE PRESIDENT
2022-07-26
STARKS DANIEL J
SOLD
-5,456,990
109.14
-50,000
-

1–10 of 50

Robert B. Ford
65535
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

ABT Income Statement

2022-09-30
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 10,410$ 10,928$ 33,562$ 31,607
Cost of products sold, excluding amortization of intangible assets4,6294,42314,54913,771
Amortization of intangible assets4985201,5171,533
Research and development7826722,1631,980
Selling, general and administrative2,7312,7678,2758,276
Total operating cost and expenses8,6408,38226,50425,560
Operating earnings1,7702,5467,0586,047
Interest expense141133404402
Interest (income)(55)(10)(95)(32)
Net foreign exchange (gain) loss194167
Other (income) expense, net(93)(74)(253)(214)
Earnings before taxes1,7582,4936,9865,884
Taxes on earnings3233931,086802
Net Earnings$ 1,435$ 2,100$ 5,900$ 5,082
Basic Earnings Per Common Share (in dollars per share)$ 0.82$ 1.18$ 3.35$ 2.85
Diluted Earnings Per Common Share (in dollars per share)$ 0.81$ 1.17$ 3.32$ 2.83
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)1,752,9681,774,5161,756,2091,776,870
Dilutive Common Stock Options (in shares)10,68514,48311,63814,407
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)1,763,6531,788,9991,767,8471,791,277
Outstanding Common Stock Options Having No Dilutive Effect (in shares)5,4452,7402,6552,694

ABT Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 9,594$ 9,799
Short-term investments313450
Trade receivables, less allowances of $520 in 2022 and $519 in 20216,4086,487
Inventories:  
Finished products3,4073,081
Work in process726694
Materials1,6011,382
Total inventories5,7345,157
Prepaid expenses and other receivables2,7962,346
Total Current Assets24,84524,239
Investments764816
Property and equipment, at cost19,30619,364
Less: accumulated depreciation and amortization10,61710,405
Net property and equipment8,6898,959
Intangible assets, net of amortization10,85012,739
Goodwill22,28423,231
Deferred income taxes and other assets5,3695,212
Total Assets72,80175,196
Current Liabilities:  
Trade accounts payable4,1334,408
Salaries, wages and commissions1,4261,625
Other accrued liabilities5,4755,181
Dividends payable820831
Income taxes payable394306
Current portion of long-term debt1,117754
Total Current Liabilities13,36513,105
Long-term debt15,29717,296
Post-employment obligations, deferred income taxes and other long-term liabilities8,2558,771
Commitments and Contingencies
Shareholders’ Investment:  
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued00
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,42124,56024,470
Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228(14,555)(11,822)
Earnings employed in the business35,11531,528
Accumulated other comprehensive income (loss)(9,445)(8,374)
Total Abbott Shareholders’ Investment35,67535,802
Noncontrolling Interests in Subsidiaries209222
Total Shareholders’ Investment35,88436,024
Total Liabilities and Shareholders' Investment$ 72,801$ 75,196